Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Axsome Therapeutics, Inc.
< Previous
1
2
Next >
Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference
October 24, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Appoints Dr. Sue Mahony to its Board of Directors
October 11, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report Third Quarter 2023 Financial Results on November 6
October 10, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Joins the National Alliance on Mental Illness and Others Advocating for the Importance of Mental Health on Mental Illness Awareness Week
October 02, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Joins the Global Narcolepsy Community in Raising Awareness on World Narcolepsy Day
September 21, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Highlights Commitment to Innovating Treatments for Mental Health Conditions with Presentations at Psych Congress 2023
September 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at Three Upcoming Investor Conferences
September 05, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report Second Quarter 2023 Financial Results on August 7
July 12, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Adults
July 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
June 30, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
June 28, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
June 27, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
June 01, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
May 30, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
May 08, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
May 03, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
May 01, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of
April 21, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 14, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8
April 13, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference
March 01, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 27, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe
February 22, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 07, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
January 31, 2023
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022
December 07, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation
November 28, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference
November 23, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference
November 09, 2022
From
Axsome Therapeutics, Inc.
Via
GlobeNewswire
Tickers
AXSM
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.